Abstract
Metastatic melanoma has been a very poor prognostic cancer with a median of survival between six to eight months. A lot of new therapies have been discovered these last years. Two types of treatment have emerged: immunotherapy and targeted therapy. Targeted therapies have been developed because of the discovery of new oncogenic mutations with a big impact of melanoma development. The efficacy is great with a high overall response and a good tolerance. However, most of patients escape in few months of targeted therapy. The sequence of drug using and their combination are the question for the next years.
Keywords:
BRAF inhibitor; MEK inhibitor; cKIT inhibitor; inhibiteur de BRAF; inhibiteur de MEK; inhibiteur de cKIT; metastatic melanoma; métastatique.
Copyright © 2014 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Imidazoles / therapeutic use
-
Indoles / therapeutic use
-
MAP Kinase Kinase Kinase 1 / antagonists & inhibitors
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Melanoma / secondary*
-
Molecular Targeted Therapy / methods*
-
Neoplasm Proteins / antagonists & inhibitors*
-
Oximes / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Pyridones / therapeutic use
-
Pyrimidinones / therapeutic use
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Sulfonamides / therapeutic use
-
Vemurafenib
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Indoles
-
Neoplasm Proteins
-
Oximes
-
Protein Kinase Inhibitors
-
Pyridones
-
Pyrimidinones
-
Sulfonamides
-
Vemurafenib
-
trametinib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
MAP Kinase Kinase Kinase 1
-
dabrafenib